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April 2017 trial indicated that insulin resistance was a new target of second prevention of stroke for patients with ischemic stroke and transient ischemic attack. However, in the IRIS trial, all the patients were white, and β cell function showed ethnic differences between white and Asians, 17 which may influence the relationship between insulin resistance and outcome of stroke. Thus, whether insulin resistance could predict stroke prognosis in the Chinese population is still unclear. Furthermore, all the patients in the IRIS trial had a nonacute stroke, and whether insulin resistance in the acute phase of stroke could lead to poor prognosis is also unclear.
By using data derived from the ACROSS-China registry (Abnormal Glucose Regulation in Patients With Acute Stroke Across China), we examined the association between insulin resistance and the clinical outcomes in nondiabetic patients after first-ever acute ischemic stroke.
Methods

Study Cohort and Participants
Ischemic stroke patients without a history of diabetes mellitus in the ACROSS-China registry were included in this study. ACROSSChina is a nationwide prospective hospital-based registry that aimed to investigate the prevalence and distribution of cases of abnormal glucose regulation, the current situation of abnormal glucose regulation in hospitalized patients with a first-ever stroke within 14 days after onset, and abnormal glucose regulation on the outcome of these patients from 2008 to 2009 in 49 sites across China. The rationale, design, and main results of this study have been previously described. [18] [19] [20] The ACROSS-China protocol and data collection were approved by the ethics committee of Beijing Tiantan Hospital. Written informed consent was obtained from all the patients or their representatives before data collection. Acute ischemic stroke was diagnosed in accordance with the World Health Organization criteria 21 with confirmation by using brain computed tomography or magnetic resonance. The diagnostic criteria were consistent across all the participating hospitals with a standard protocol.
Data Collection and Risk Factors
Baseline data on demographic characteristics, cardiovascular risk factors, medical history, and medical treatments were collected within 24 hours after admission through face-to-face interviews by trained interviewers (neurologists from participating hospitals). Baseline information included sex, age, height, weight, blood pressure, lowdensity lipoprotein (LDL), high-density lipoprotein level, triglyceride level, body mass index (calculated as the measured weight [kg] divided by the square of the measured height [m 2 ]), and current or previous smoking. Medical history included a history of hypertension, dyslipidemia, diabetes mellitus, atrial fibrillation (history of atrial fibrillation confirmed by at least one ECG), and coronary heart disease.
Stroke severity was evaluated by using the National Institutes of Health Stroke Scale within 24 hours after admission. The etiologic subtypes of ischemic stroke were classified in accordance with the Trial of ORG 10172 in acute stroke treatment. 22 The occurrence of pulmonary or urinary infection complications and the medication used during hospitalization were also recorded.
Insulin Resistance Evaluation
Fasting venous blood samples were drawn to measure fasting insulin and fasting glucose levels on day 14±3 after stroke onset or prior to discharge (if hospital stay was <14 days) after overnight fasting (at least 8 hours). Insulin level was measured by using a competitive radioimmunoassay (Diagnostic Products Corporation), and glucose was measured by using an enzymatic method. 6 The homeostatis model assessment-insulin resistance (HOMA-IR; calculated as fasting insulin [μU/mL]×fasting glucose [mmol/L]/22.5) was used to identify patients with insulin resistance. 23 Insulin resistance was defined as a HOMA-IR index within the top quartile as reported in a previous study.
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Patient Follow-Up and Outcome Evaluation
At 12 months after stroke onset, the prognoses of all the patients were assessed through a centralized telephone follow-up. The telephone follow-up was based on a shared standardized interview protocol with blinding to the HOMA-IR condition. The outcomes included all-cause mortality, stroke recurrence, and poor functional outcome at 12 months. Stroke recurrence was defined as aggravated primary neurological deficit, a new neurological deficit, or rehospitalization with a diagnosis of ischemic or hemorrhagic stroke. Poor functional outcome was defined as modified Rankin scale scores of 3 to 6. Dependence was defined as modified Rankin scale scores of 3 to 5.
Statistical Analysis
The demographic and clinical characteristics were compared in accordance with quartiles of the HOMA-IR index by using the χ 2 test for categorical variables and analysis of variance or Kruskal-Wallis test for continuous variables, respectively. The HOMA-IR index was examined continuously and as quartiles to investigate a potential dose-response relationship with the outcome of ischemic stroke. The crude and multivariable-adjusted hazard ratio (HR) with their 95% confidence intervals (CIs) for stroke recurrence and death were estimated by using a Cox regression model, while odds ratios (OR) with their 95% CIs for poor functional outcome at 12 months were estimated by using a logistic regression model. All significant covariates in the univariable analysis were included in the multivariable model. We further evaluated the associations between HOMA-IR and risk of outcomes by using a Cox or logistic regression model with restricted cubic splines for HOMA-IR. The 5 knots for the spline were placed at the 5th, 25th, 50th, 75th, and 95th percentiles of the HOMA-IR, and the first quartile of the HOMA-IR was treated as the reference.
All data were analyzed with the SAS version 9.4 software (SAS Institute Inc, Cary, NC). In this study, we were more interested in the comparison-wise error rate for each single outcome instead of the experiment-wise error rate; therefore, correction for multiple comparisons was not performed in this analysis. 24 All P values were 2-sided, with P values <0.05 considered significant. 
Results
In this study, 2639 stroke patients were enrolled, 534 of whom were excluded because of a history of diabetes mellitus. Among the remaining 2105 patients, 544 had no data on fasting insulin and glucose levels and were also excluded. After further exclusion of 316 patients for lack of 12-month follow-up, 1245 patients were included in the final analysis ( Figure 1 ). No significant difference in baseline characteristics was found between the study patients and those who were excluded for missing data on fasting insulin and glucose levels or loss to follow-up (Table I in 
Baseline Characteristics
The baseline characteristics of the included 1245 nondiabetic ischemic stroke patients according to HOMA-IR quartiles are shown in Table 1 . The mean age of the study subjects was 62.3±12.9 years, and 782 (63.1%) patients were male. The . By using a regression model with a restricted cubic spline, we found that a higher HOMA-IR index was associated with an increased risk of 12-month stroke recurrence, death, and poor outcome with a threshold of 2.5 ( Figure 2 ).
One-Year Clinical Outcomes According to Insulin Resistance
Among the 1245 nondiabetic ischemic stroke patients enrolled, 305 (24.5%) had insulin resistance. Body mass index (OR, 1.06; 95% CI, 1.02-1.09; P=0.002) and triglyceride level at admission (OR, 1.32; 95% CI 1.17-1.49; P<0.001) were independently associated with insulin resistance in a multivariate logistic model.
Compared with the patients without insulin resistance, those with insulin resistance were associated with increased (Table 3) . No significant association was observed between insulin resistance and dependence at 1 year in patients with ischemic stroke.
Discussion
In this large-scale, hospital-based, prospective cohort study, we found that insulin resistance was associated with 1-year death, stroke recurrence, and poor outcome but not with dependence in nondiabetic patients with acute ischemic stroke. Although previous studies confirmed that insulin resistance was associated with increased risk of coronary heart disease, stroke, and cognitive impairment in the general population, only a few studies investigated the relationship between insulin resistance and the prognosis in ischemic stroke. [13] [14] [15] Some studies indicated that insulin resistance might be associated with worsening of outcome after thrombolytic therapy for acute ischemic stroke.
13,14 A preliminary study showed that insulin resistance in combination with decreased insulin secretion might be associated with the recurrence of ischemic stroke or ischemic heart disease, but the study could not draw a definite conclusion because of the limited sample size. 15 This study provides evidence of association between insulin resistance and poor prognosis of stroke patients based on a largescale study of a Chinese population.
Insulin resistance is caused by defective intracellular signaling that affects glucose transport and other biochemical events. Insulin resistance is a syndrome that is associated with a clustering of metabolic disorders, including diabetes mellitus, obesity, hypertension, and lipid abnormalities, 3, 25, 26 which are all important risk factors of stroke occurrence 27 and stroke recurrence. 28 The physiological consequences of insulin resistance include metabolic and cellular changes that may promote atherosclerosis, 3 which were also identified as major causes of ischemic stroke, especially in the Chinese population. Insulin resistance also affects a majority of nondiabetic patients with ischemic stroke or transient ischemic attack. 2 In our study, we found that patients with metabolic disorders, such as higher body mass index and triglyceride levels on admission, were more likely to have higher HOMA-IR index or insulin resistance. Overall, insulin resistance is not simply a 
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problem of deficient glucose uptake in response to insulin but is a multifaceted syndrome that increases significantly the risk of stroke and leads to poor outcomes in patients with stroke.
There was no definite definition of insulin resistance, and most previous studies performed analysis according to quartiles of the HOMA-IR index and defined insulin resistance by the top quartile (Q4) of the HOMA-IR index. 5, 29 These studies showed that the cutoff point of the fourth quartile of the HOMA-IR index in Western populations (2.8-3.3) was close to 3.1 reported in our study. We performed the analysis according the HOMA-IR quartile categories and showed that patients with the third quartile of the HOMA-IR index were also significantly associated with an increased risk of poor prognosis.
Our study shows that insulin resistance confirmed in the acute phase was associated with an increased rate of death at 1 year and stroke recurrence in nondiabetic patients with acute ischemic stroke, while patients with stroke in IRIS trial were all in nonacute phase. 16 Our finding indicates that testing for insulin resistance should be considered in nondiabetic patients with ischemic stroke during their hospitalization to identify those with metabolic disorders. Furthermore, the IRIS trial 16 indicated that pioglitazone therapy could decrease the risk of vascular events in stroke or transient ischemic attack patients with metabolic syndrome. The results of the IRIS trial showed that patients with insulin resistance should be treated to reduce their risk of a subsequent stroke and heart disease. Early treatment with pioglitazone could be considered for nondiabetic patients with ischemic stroke or transient ischemic attack in the acute phase.
Our study had several limitations. First, all the participating hospitals were from urban regions of China, where quality of stroke care was better than that in rural hospitals. Second, the pathophysiology of ischemic stroke in Chinese patients is different from that in Western patients and has a much higher incidence of large artery atherosclerosis. This limits the generalizability of the findings to a Western population where different stroke subtypes are more prevalent. Third, among the 2105 patients who met the inclusion criteria, 854 (40%) were excluded because they were not tested for HOMA-IR index or were lost to follow-up in 1 year. However, the baseline characteristics between the study patients and those excluded were well balanced. Fourth, selection bias may have existed because most of the patients in our study had a mild ischemic stroke. A standard oral glucose tolerance test was required to be performed in all the patients without previous diabetes mellitus in the ACROSSChina registry. Therefore, several patients with severe clinical symptom, such as coma and dysphagia, could not complete the oral glucose tolerance test and were excluded. Further studies are needed to confirm the results in patients with a severe stroke.
Conclusions
In conclusion, insulin resistance was associated with increased risk of death, stroke recurrence, and poor outcome but not dependence in nondiabetic patients with ischemic stroke. 
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